猪丹毒丝菌灭活疫苗免疫佐剂的筛选

doi:10.11843/j.issn.0366-6964.2020.05.019

摘要/Abstract

摘要： 旨在筛选适宜于猪丹毒丝菌灭活疫苗的佐剂。以分离鉴定出的猪丹毒丝菌1a型HG-1株灭活菌体为抗原分别配制矿物油佐剂疫苗（简称矿物油疫苗）、氢氧化铝胶佐剂疫苗（简称铝胶疫苗）、ISA201双相油乳佐剂疫苗（简称ISA201疫苗）、GEL02水溶性聚合物佐剂疫苗（简称GEL疫苗）、IMS1313水溶性纳米佐剂疫苗（简称IMS1313疫苗）共5种佐剂的灭活疫苗。小鼠免疫保护试验结果表明，二免14 d后使用约为4 LD₅₀的HG-1株对小鼠进行腹腔攻毒，矿物油疫苗和GEL疫苗的保护率分别为100%（7/7）和71%（5/7），其他三种佐剂疫苗的保护率均为14%（1/7）。本研究进一步选择铝胶疫苗和GEL疫苗进行猪体对比试验；仔猪安全性试验结果表明，两种佐剂疫苗的副反应均较小；免疫保护试验结果表明，两次免疫后使用约为16 LD₁₀₀的HG-1株对免疫仔猪进行耳缘静脉攻毒，两种佐剂疫苗的保护率分别为60%（3/5）和100%（5/5）。本研究最终选择GEL佐剂作为开发猪丹毒灭活疫苗的最适佐剂。

关键词: 猪, 猪丹毒丝菌, 疫苗, 佐剂

Abstract: The objective of this study was to screen the adjuvant suitable for an inactivated vaccine against Erysipelothrix rhusiopathiae. The five inactivated vaccines of mineral oil adjuvant (referred as oil vaccine), aluminum hydroxide adjuvant (referred as alh vaccine), ISA201 dual phase oil emulsion adjuvant (referred as ISA201vaccine), GEL02 water-soluble polymer adjuvant (referred as GEL vaccine), and IMS1313 water-soluble nano-sized adjuvant (referred as IMS1313 vaccine) were prepared, which the antigens of that were all inactivated bacteria of E. rhusiopathiae strain HG-1, isolated and identified as serovar 1a. The immunoprotection test results of the mouse showed that after 14 days of second immunization, mice were intraperitoneally challenged with 4LD₅₀ HG-1 solution, giving the protection rates of the five vaccines 100% (7/7), 14% (1/7), 14% (1/7), 71% (5/7) and 14% (1/7), respectively. According to the above test results, the safety test of piglets was carried out by using alh vaccine and GEL vaccine, and the results showed that the side effects of the two adjuvant vaccines were small. Fourteen days after the second immunization, groups of pigs vaccinated with alh vaccine and GEL vaccine were challenged intravenously with 16 LD₁₀₀ of HG-1 solution, and the results showed that alh vaccine and GEL vaccine provide 60% (3/5) and 100% (5/5) protective efficacy, respectively. This study identified GEL adjuvant as the optimal adjuvant for the development of an inactivated vaccine against swine erysipelas.

Key words: swine, Erysipelothrix rhusiopathiae, vaccine, adjuvant

中图分类号:

S858.285.1

裴世璇, 宋吉健, 韩忆侬, 薛云, 王臣, 司丽芳, 赵战勤. 猪丹毒丝菌灭活疫苗免疫佐剂的筛选[J]. 畜牧兽医学报, 2020, 51(5): 1083-1090.

PEI Shixuan, SONG Jijian, HAN Yinong, XUE Yun, WANG Chen, SI Lifang, ZHAO Zhanqin. Comparison of Adjuvant for Inactivated Swine Erysipelas Vaccines against Erysipelothrix rhusiopathiae[J]. Acta Veterinaria et Zootechnica Sinica, 2020, 51(5): 1083-1090.

参考文献 39

[1]	BROOKE C J, RILEY T V. Erysipelothrix rhusiopathiae:bacteriology, epidemiology and clinical manifestations of an occupational pathogen[J]. J Med Microbiol, 1999, 48(9):789-799.
[2]	WANG Q N, CHANG B J, RILEY T V. Erysipelothrix rhusiopathiae[J]. Vet Microbiol, 2010, 140(3-4):405-417.
[3]	FIORITO C D, BENTANCOR A, LOMBARDO D, et al. Erysipelothrix rhusiopathiae isolated from gull-inflicted wounds in southern right whale calves[J]. Dis Aquat Organ, 2016, 121(1):67-73.
[4]	ERSDAL C, JØRGENSEN H J, LIE K I. Acute and chronic Erysipelothrix rhusiopathiae infection in lambs[J]. Vet Pathol, 2015, 52(4):635-643.
[5]	JANßEN T, VOSS M, KVHI M, et a1. A combinational approach of multilocus sequence typing and other molecular typing methods in unravelling the epidemiology of Erysipelothrix rhusiopathiae strains from poultry and mammals[J]. Vet Res, 2015, 46(1):84.
[6]	UPAPAN P. Human Erysipelothrix rhusiopathiae infection:unsolved issues and possible solutions[J]. J Med Assoc Thai, 2015, 98 Suppl 9:S170-S176.
[7]	MCNEIL M, GERBER P F, THOMSON J, et al. Serotypes and Spa types of Erysipelothrix rhusiopathiae isolates from British pigs (1987 to 2015)[J]. Vet J, 2017, 225:13-15.
[8]	王明俊, 刘礼恒, 周泰冲, 等. 猪瘟、猪丹毒、猪肺疫三种疫苗的同时免疫试验[J]. 畜牧兽医学报, 1957, 2(2):113-116.WANG M J, LIU L H, ZHOU T C, et al. An experimental study of the simultaneous immunization with swine erysipelas, swine fever, and swine pasteurellosis vaccines[J]. Acta Veterinaria et Zootechnica Sinica, 1957, 2(2):113-116. (in Chinese)
[9]	ZOU Y, ZHU X M, MUHAMMAD H M, et al. Characterization of Erysipelothrix rhusiopathiae strains isolated from acute swine erysipelas outbreaks in Eastern China[J]. J Vet Med Sci, 2015, 77(6):653-660.
[10]	DING Y, ZHU D M, ZHANG J M, et al. Virulence determinants, antimicrobial susceptibility, and molecular profiles of Erysipelothrix rhusiopathiae strains isolated from China[J]. Emerg Microbes Infect, 2015, 4(11):e69.
[11]	WOOD R L, HAUBRICH D R, HARRINGTON R Jr. Isolation of previously unreported serotypes of Erysipelothrix rhusiopathiae from swine[J]. Am J Vet Res, 1978, 39(12):1958-1961.
[12]	OGAWA Y, SHIRAIWA K, NISHIKAWA S, et al. Identification of the chromosomal region essential for serovar-specific antigen and virulence of serovar 1 and 2 strains of Erysipelothrix rhusiopathiae[J]. Infect Immun, 2018, 86(9):e00324-18.
[13]	JIN X H, ZHENG L L, SONG M R, et al. A Nano silicon adjuvant enhances inactivated transmissible gastroenteritis vaccine through activation the Toll-like receptors and promotes humoral and cellular immune responses[J]. Nanomed:Nanotechnol, Biol Med, 2018, 14(4):1201-1212.
[14]	REED S G, BERTHOLET S, COLER R N, et al. New horizons in adjuvants for vaccine development[J]. Trends Immunol, 2009, 30(1):23-32.
[15]	农业部兽用生物制品规程委员会. 中华人民共和国兽用生物制品规程(2000年版)[M]. 北京:化学工业出版社, 2000:34-37.Regulation Committee of Vetevinary Biological Products, Ministry of Agriculture and Rural Affairs. Procedures of veterinary biological products of the People's Republic of China[M]. Beijing:Chemical Industry Press, 2000:34-37. (in Chinese)
[16]	ROSSKOPF-STREICHER U, JOHANNES S, WILHELM M, et al. Quality control of inactivated erysipelas vaccines:results of an international collaborative study to establish a new regulatory test[J]. Vaccine, 2001, 19(11-12):1477-1483.
[17]	BOCHNER B R. New technologies to assess genotype-phenotype relationships[J]. Nat Rev Genet, 2003, 4(4):309-314.
[18]	SHIRAIWA K, OGAWA Y, NISHIKAWA S, et al. Identification of serovar 1a, 1b, 2, and 5 strains of Erysipelothrix rhusiopathiae by a conventional gel-based PCR[J]. Vet Microbiol, 2018, 225:101-104.
[19]	徐引弟, 王治方, 朱文豪, 等. 副猪嗜血杆菌高免血清的制备与应用[J]. 中国农学通报, 2010, 26(13):14-16.XU Y D, WANG Z F, ZHU W H, et al. Preparation and application of hyper immunized serum of Haemophilus parasuis[J]. Chinese Agricultural Science Bulletin, 2010, 26(13):14-16. (in Chinese)
[20]	XUE Q, ZHAO Z Q, LIU H S, et al. First comparison of adjuvant for trivalent inactivated Haemophilus parasuis serovars 4, 5 and 12 vaccines against Glässer's disease[J]. Vet Immunol Immunopathol, 2015, 168(3-4):153-158.
[21]	BEGG D J, DHUNGYEL O, NADDI A, et al. The immunogenicity and tissue reactivity of Mycobacterium avium subsp paratuberculosis inactivated whole cell vaccine is dependent on the adjuvant used[J]. Heliyon, 2019, 5(6):e01911.
[22]	JANG S I, LILLEHOJ H S, LEE S H, et al. Immunoenhancing effects of MontanideTM ISA oil-based adjuvants on recombinant coccidia antigen vaccination against Eimeria acervulina infection[J]. Vet Parasitol, 2010, 172(3-4):221-228.
[23]	DAR P, KALAIVANAN R, SIED N, et al. Montanide ISATM 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle[J]. Vaccine, 2013, 31(33):3327-3332.
[24]	El-SAYED IBRAHIM E, GAMAL W M, HASSAN A I, et al. Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine[J]. Vet World, 2015, 8(10):1189-1198.
[25]	BOUGUYON E, GONCALVES E, SHEVTSOV A, et al. A new adjuvant combined with inactivated influenza enhances specific CD8 T cell response in mice and decreases symptoms in swine upon challenge[J]. Viral Immunol, 2015, 28(9):524-531.
[26]	薛云, 李静, 王臣, 等. 羊源致病性柠檬酸杆菌4种佐剂灭活疫苗的免疫效果比较[J]. 中国预防兽医学报, 2018, 40(8):726-731.XUE Y, LI J, WANG C, et al. Comparison of four kinds of adjuvants for inactivated Citrobacter freundii vaccine in sheep[J]. Chinese Journal of Preventive Veterinary Medicine, 2018, 40(8):726-731. (in Chinese)
[27]	XU Y X, WANG Q, WEI B W, et al. Enhanced immune responses against japanese encephalitis virus infection using Japanese encephalitis live-attenuated virus adjuvanted with montanide GEL 01 ST in mice[J]. Vector Borne Zoonotic Dis, 2019, 19(11):835-843, doi:10. 1089/vbz. 2018. 2419.
[28]	TABYNOV K, SANSYZBAY A, TULEMISSOVA Z, et al. Inactivated porcine reproductive and respiratory syndrome virus vaccine adjuvanted with MontanideTM Gel 01 ST elicits virus-specific cross-protective inter-genotypic response in piglets[J]. Vet Microbiol, 2016, 192:81-89.
[29]	AROUS J B, BERTRAND F, GAUCHERON J, et a1. Adjuvant formulations designed to improve swine vaccine stability:application to PCV2 vaccines[J]. Procedia Vaccinol, 2013, 7:34-39.
[30]	MATHEW M K, VIRMANI N, BERA B C, et al. Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with MontanideTM Pet Gel in murine model[J]. J Vet Med Sci, 2019, 81(12):1753-1762, doi:10. 1292/jvms. 19-0399.
[31]	DI GIACOMO S, QUATTROCCHI V, ZAMORANO P. Use of adjuvants to enhance the immune response induced by a DNA vaccine against bovine herpesvirus-1[J]. Viral Immunol, 2015, 28(6):343-346.
[32]	CAUCHARD S, BERTRAND F, BARRIER-BATTUT I, et al. Assessment of the safety and immunogenicity of Rhodococcus equi-secreted proteins combined with either a liquid nanoparticle (IMS 3012) or a polymeric (PET GEL A) water-based adjuvant in adult horses and foals-identification of promising new candidate antigens[J]. Vet Immunol Immunopathol, 2014, 157(3-4):164-174.
[33]	PETERMANN J, BONNEFOND R, MERMOUD I, et al. Evaluation of three adjuvants with respect to both adverse effects and the efficacy of antibody production to the Bm86 protein[J]. Exp Appl Acarol, 2017, 72(3):303-315.
[34]	ZHAO Z Q, LIU H S, ZHANG K S, et al. Minimum dose, antigen content, and immunization duration of a trivalent vaccine of inactivated Haemophilus parasuis serovars 4, 5, and 12 against Glässer's disease in pigs[J]. Can J Vet Res, 2016, 80(4):287-293.
[35]	ZHAO Z Q, LIU H S, XUE Y, et al. Analysis of efficacy obtained with a trivalent inactivated Haemophilus parasuis serovars 4, 5, and 12 vaccine and commercial vaccines against Glasser's disease in piglets[J]. Can J Vet Res, 2017, 81(1):22-27.
[36]	HE P, ZOU Y N, HU Z Y. Advances in aluminum hydroxide-based adjuvant research and its mechanism[J]. Hum Vaccin Immunother, 2015, 11(2):477-488.
[37]	MA X, GUO Z H, SHEN Z Q, et al. The immune enhancement of propolis adjuvant on inactivated porcine parvovirus vaccine in guinea pig[J]. Cell Immunol, 2011, 270(1):13-18.
[38]	HARANDI A M, MEDAGLINI D, SHATTOCK R J, et al. Vaccine adjuvants:a priority for vaccine research[J]. Vaccine, 2010, 28(12):2363-2366.
[39]	张珍珍, 韦艳娜, 王佳, 等. GEL01佐剂联合猪支原体肺炎活疫苗黏膜接种的效果评估[J]. 中国动物传染病学报, 2018, 26(6):73-79.ZHANG Z Z, WEI Y N, WANG J, et al. GEL01 adjuvant enhances mucosal immunity of live Mycoplasma hyopneumoniae vaccine[J]. Chinese Journal of Animal Infectious Diseases, 2018, 26(6):73-79. (in Chinese)